Skip to main content

Galera Therapeutics, Inc.

GRTXDelisted Sep 6, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001563577

Galera Therapeutics, Inc. was delisted on Sep 6, 2024; its insiders filed their last Form 4 on Aug 5, 2026; 36 institutions reported holding it in 13F filings for Q1 2024, worth $1.37M in total; no superinvestor held it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
36
Q1 2024, −1 vs. previous quarter
13F value
$1.37M
Reported value at the end of Q1 2024
Superinvestors holding
0
At the end of Q1 2024

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
$149.0M
No comparable prior period
Free cash flow, FY2025
–
No comparable prior period
Revenue, Q1 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Jun 30, 2026.

Short interest
7.37K
Shares sold short
Change
+646
+9.6% vs. previous
Days to cover
1.00
At average daily volume

Superinvestors holding GRTX, Q1 2024

Go to the superinvestors tab

No superinvestor reported holding GRTX at the end of Q1 2024.

Latest insider trades

See all insider trades

Open-market purchases and sales by Galera Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 24, 2025 (view filing)4:42 PM ETNov 204 daysSorensen MelPresident and CEOSSale−70.0K$0.0201−$1.41K−26.4%195.0K after
Jan 2, 2025 (view filing)4:12 PM ETDec 30, 20243 daysChang Nancy TDirector, 10% OwnerPPurchase+7.64M$0.0654+$500.0KNew position7.64M after
Aug 20, 2024 (view filing)4:45 PM ETAug 164 daysSorensen MelPresident and CEOSSale−67.0K$0.072−$4.83K−20.2%265.0K after
May 1, 2024 (view filing)5:02 PM ETApr 17, 2014-Apr 19, 20243,667 daysSchneid Yair10% OwnerPPurchase+2.78M$0.2124+$590.4K+34.6%10.8M afterAmended21 lots
Mar 20, 2023 (view filing)Mar 164 daysBachleda MarkChief Commercial OfficerPPurchase+11.0K$2.25+$24.8KNew position11.0K after
Mar 14, 2023 (view filing)Mar 104 daysSorensen MelPresident and CEOPPurchase+100.0K$1.68+$168.0K+43.1%332.0K after
Mar 14, 2023 (view filing)Mar 131 dayDegnan ChrisChief Financial OfficerPPurchase+10.0K$1.96+$19.6KNew position10.0K after
Dec 20, 2021 (view filing)Dec 173 daysWest LindaDirectorPPurchase+20.0K$2.74+$54.8K+50.0%60.0K after
Sep 3, 2021 (view filing)Sep 12 daysHolmlund Jon TChief Medical OfficerSSale−47.8K$8.47−$404.5K−100.0%0 after

Top 10 13F holders, Q1 2024

See all 36 holders

The largest institutional positions in Galera Therapeutics, Inc. at the end of Q1 2024; share changes are against Q4 2023.

Institutions holding GRTX in Q1 2024
InstitutionSharesValue% of portfolioChange in sharesAction
Gsa Capital Partners LLP3,632,627$509.0K0.04%−259,934−6.7%Reduced
Blackstone Group Inc.1,678,984$235.1K0.00%00.0%Unchanged
Standard Life Aberdeen plc898,374$125.8K0.00%00.0%Unchanged
Nan Fung Group Holdings Ltd613,223$85.9K0.08%00.0%Unchanged
Vanguard Group Inc448,330$62.8K0.00%00.0%Unchanged
Geode Capital Management, LLC440,349$61.7K0.00%00.0%Unchanged
BlackRock Inc.357,192$50.0K0.00%−430−0.1%Reduced
Atom Investors LP356,204$49.9K0.01%+356,204New
UBS Group AG293,502$41.1K0.00%+281,287+2,302.8%Added
Susquehanna International Group, LLP286,180$40.1K0.00%+286,180New

Holders of 5% or more of GRTX

See all 3 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Galera Therapeutics, Inc..

Largest holders of GRTX from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Emerald Bioventures, LLC13D/A30.20%61.0M shares+3.70 ppfrom 26.50%Apr 27, 20262 filingsMay 29, 2026SEC
Hyare Parvinder Singh13D6.65%13.5M sharesNewJun 11, 20261 filingJun 11, 2026SEC
Chang Nancy T13D5.90%8.92M sharesNewApr 10, 20261 filingApr 10, 2026SEC